MiMedx Group (MDXG) Panoramica del titolo
MiMedx Group, Inc. sviluppa e distribuisce allotrapianti di tessuto placentare per vari settori della sanità. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
MDXG Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di MiMedx Group, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$4.33 |
| Massimo di 52 settimane | US$7.97 |
| Minimo di 52 settimane | US$3.03 |
| Beta | 1.41 |
| Variazione di 1 mese | 3.10% |
| Variazione a 3 mesi | 17.98% |
| Variazione di 1 anno | -38.84% |
| Variazione a 3 anni | -40.93% |
| Variazione a 5 anni | -70.30% |
| Variazione dall'IPO | -15.10% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Aug 07
MDXG: Higher Profitability Assumptions Will Support Compelling Undervalued Upside
Analysts have lifted their fair value estimate for MiMedx Group from $5.00 to $6.00 per share, citing updated assumptions on discount rates, revenue contraction, profit margins and future P/E that together support a higher price target. What’s in the News for MiMedx Group MiMedx Group repurchased 3,464,399 shares, representing 2.33% of shares, for a total of US$12.71 million between April 1, 2026 and June 30, 2026, completing the buyback announced on February 25, 2026.Articolo di analisi • Aug 06
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Are Actually Better Than They Appear
The market for MiMedx Group, Inc.'s ( NASDAQ:MDXG ) shares didn't move much after it posted weak earnings recently. We...Aggiornamento narrativa • Jul 02
MDXG: Index Shifts And Guidance Reset Will Present Undervalued Entry Opportunity
MiMedx Group's analyst price targets have been reduced by a combined few dollars across several firms, with the new consensus anchoring to a lower fair value near $5.00 as analysts factor in softer revenue growth expectations, slightly higher profit margins, and updated P/E assumptions. Analyst Commentary Recent Street research on MiMedx Group centers on a series of price target cuts that cluster around the new consensus near US$5.00.Recent updates
Aggiornamento narrativa • Aug 07
MDXG: Higher Profitability Assumptions Will Support Compelling Undervalued Upside
Analysts have lifted their fair value estimate for MiMedx Group from $5.00 to $6.00 per share, citing updated assumptions on discount rates, revenue contraction, profit margins and future P/E that together support a higher price target. What’s in the News for MiMedx Group MiMedx Group repurchased 3,464,399 shares, representing 2.33% of shares, for a total of US$12.71 million between April 1, 2026 and June 30, 2026, completing the buyback announced on February 25, 2026.Articolo di analisi • Aug 06
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Are Actually Better Than They Appear
The market for MiMedx Group, Inc.'s ( NASDAQ:MDXG ) shares didn't move much after it posted weak earnings recently. We...Aggiornamento narrativa • Jul 02
MDXG: Index Shifts And Guidance Reset Will Present Undervalued Entry Opportunity
MiMedx Group's analyst price targets have been reduced by a combined few dollars across several firms, with the new consensus anchoring to a lower fair value near $5.00 as analysts factor in softer revenue growth expectations, slightly higher profit margins, and updated P/E assumptions. Analyst Commentary Recent Street research on MiMedx Group centers on a series of price target cuts that cluster around the new consensus near US$5.00.
Aggiornamento narrativa • Jun 18
MDXG: New Wound Care Launches Will Support Chronic Biologics Comeback Narrative
MiMedx Group's consensus analyst price target has been reduced by several dollars to reflect updated assumptions on discount rates, revenue growth, profit margins, and future P/E, with analysts citing recent target cuts from several firms as they refine their outlook on the stock. Analyst Commentary Recent research updates on MiMedx Group point to a more cautious stance on valuation, with several firms trimming price targets by varying dollar amounts.Aggiornamento narrativa • Jun 04
MDXG: Future Earnings Power Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price target on MiMedx Group by a few dollars, citing updated views on profitability and expectations for a higher future P/E multiple as key reasons for the reset. Analyst Commentary Recent Street research has focused on resetting price targets for MiMedx Group by a few dollars at a time, as analysts revisit their assumptions around profitability, execution, and what P/E multiple they are comfortable assigning to the stock.Seeking Alpha • May 09
MiMedx: The Hard Math Behind My Downgrade To Hold
Summary MiMedx Group faces a sharp downgrade from Buy to Hold as 2026 revenue guidance drops to $260–$290 million from $340–$360 million. Q1 2026 saw a 33% revenue decline, with wound care sales down 60% and surgical portfolio growth at 13%, reflecting permanent reimbursement headwinds. My DCF model, updated for lower revenue and margin assumptions, now values MDXG at $3.93 per share—just 6% above the current price, making upside limited. Management targets breakeven in Q3 via $40 million cost cuts, but execution risk remains high amid industry 'fire sale' conditions and uncertain wound care recovery. Read the full article on Seeking AlphaAggiornamento narrativa • May 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Comeback Narrative
Analysts have trimmed their average price targets on MiMedx Group by several dollars to reflect lower fair value estimates, softer revenue and margin assumptions, and a higher implied future P/E, as highlighted in recent research updates from multiple firms. Analyst Commentary Recent research on MiMedx Group highlights a mixed set of views, with several firms lowering price targets while still pointing to specific factors that could support value over time.
Nuova narrativa • May 03
Surgical Adoption And Cost Cuts Will Reshape Long Term Potential For This Biologics Supplier
Catalysts About MiMedx Group MiMedx Group develops and markets placental tissue and related biologic products for wound care and surgical applications. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Apr 20
MDXG: Medicare Policy Reset Will Support Chronic Wound Biologics Recovery Narrative
Analysts have trimmed the average price target for MiMedx Group from about $9.67 to $8.20, citing updated assumptions for revenue growth, profit margins, and a higher future P/E following a series of recent target cuts across the Street. Analyst Commentary Recent Street research on MiMedx Group centers on how Medicare reimbursement decisions and updated modeling are feeding into price targets, ratings, and expectations for future execution.Nuova narrativa • Apr 18
Reimbursement And Competition Will Pressure Margins Yet Long Term Surgical Demand Will Support Upside
Catalysts About MiMedx Group MiMedx Group develops and commercializes human placental tissue and complementary products for Wound Care and Surgical applications. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Apr 05
MDXG: Medicare Reimbursement Reset Will Support Chronic Wound Biologics Recovery Narrative
The consolidated analyst price target for MiMedx Group now reflects a modest adjustment of cents per share, as analysts weigh ongoing Medicare reimbursement changes and recent coverage initiations that highlight both prior headwinds and the potential for a rebound in chronic wound biologics. Analyst Commentary Recent research updates show a mix of optimism and caution around MiMedx Group, with views largely shaped by Medicare reimbursement shifts and how these might influence the value investors place on the chronic wound biologics portfolio.Aggiornamento narrativa • Mar 22
MDXG: CMS Reimbursement Reset Will Set Up Biologics Comeback Narrative
Analysts have adjusted their MiMedx Group price targets, with recent moves ranging from $8 to $10 per share as they factor in shifting Medicare reimbursement developments and a potential recovery from prior headwinds. Analyst Commentary Recent research on MiMedx Group reflects a mix of optimism about potential recovery and caution around reimbursement and execution risk, which feeds directly into the range of price targets between $8 and $10 per share.Aggiornamento narrativa • Mar 07
MDXG: Wound Care Expansion And CMS Reset Will Support Future Rebound
The analyst price target for MiMedx Group has shifted modestly to about $9.67 per share, as analysts factor in recent reimbursement headwinds that weighed on the stock, while still noting potential upside with fresh targets such as $10 from new coverage and $8 from revised models. Analyst Commentary Recent research updates around MiMedx highlight a mix of optimism about the core wound care franchise and caution around reimbursement uncertainty and valuation reset.Aggiornamento narrativa • Feb 21
MDXG: Wound Care Portfolio Expansion Will Offset CMS Reimbursement Uncertainty
Analysts have trimmed their price targets on MiMedx Group, with one key target moving from $12 to $8, as they revisit growth, margin and P/E assumptions following recent CMS related reimbursement updates. Analyst Commentary Recent research updates point to a reset in expectations for MiMedx Group, as analysts update their models following the CMS reimbursement developments and pull back their price targets.Aggiornamento narrativa • Feb 06
MDXG: Wound Care Portfolio Expansion Will Drive Future Upside Potential
Analysts have reduced their price target on MiMedx Group to about US$10.40 from roughly US$11.00. This change reflects slightly more cautious assumptions on fair value, revenue growth, profit margins, and future P/E multiples following recent research updates.Aggiornamento narrativa • Jan 22
MDXG: Execution On Wound Care Expansion Will Drive Future Upside Potential
Analysts have trimmed their fair value estimate for MiMedx Group from US$12.20 to US$11.00, citing updated assumptions around discount rates, revenue growth, margins, and future P/E multiples as the key drivers behind the change. Analyst Commentary Recent Street research includes lower price targets from different firms that both bring MiMedx Group’s fair value range closer to the updated estimate.Articolo di analisi • Jan 09
Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...Articolo di analisi • Nov 06
MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture
MiMedx Group, Inc.'s ( NASDAQ:MDXG ) stock was strong despite it releasing a soft earnings report last week. We think...Articolo di analisi • Jul 04
MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Apr 17
Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may...Articolo di analisi • Mar 27
MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Articolo di analisi • Mar 05
Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings
The market was pleased with the recent earnings report from MiMedx Group, Inc. ( NASDAQ:MDXG ), despite the profit...Articolo di analisi • Feb 22
Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Articolo di analisi • Dec 23
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Nov 21
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Articolo di analisi • Nov 06
There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
MiMedx Group, Inc. ( NASDAQ:MDXG ) shares have had a really impressive month, gaining 27% after a shaky period...Rendimenti per gli azionisti
| MDXG | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | 3.3% | 6.3% | -1.2% |
| 1Y | -38.8% | 47.2% | 18.3% |
Ritorno vs Industria: MDXG ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 47.2 % nell'ultimo anno.
Rendimento vs Mercato: MDXG ha avuto una performance inferiore al mercato US che ha registrato un rendimento 18.3 % nell'ultimo anno.
Volatilità dei prezzi
| MDXG volatility | |
|---|---|
| MDXG Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Prezzo delle azioni stabile: MDXG non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di MDXG è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2006 | 808 | Joe Capper | www.mimedx.com |
MiMedx Group, Inc. sviluppa e distribuisce allotrapianti di tessuto placentare per vari settori della sanità. L'azienda lavora la membrana dei tessuti placentari umani, il cordone ombelicale e il disco placentare utilizzando il suo processo brevettato e proprietario PURION per produrre allotrapianti che conservano le proprietà biologiche intrinseche del tessuto e le proteine regolatrici, tra cui citochine, chemochine e fattori di crescita. Il suo metodo di lavorazione brevettato e proprietario impiega tecniche di lavorazione asettiche oltre alla sterilizzazione terminale.
MiMedx Group, Inc. Riepilogo dei fondamenti
| MDXG statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$631.14m |
| Utili (TTM) | US$6.24m |
| Ricavi(TTM) | US$355.17m |
101.2x
Rapporto P/E1.8x
Rapporto P/SMDXG è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| MDXG Conto economico (TTM) | |
|---|---|
| Ricavi | US$355.17m |
| Costo del fatturato | US$75.12m |
| Profitto lordo | US$280.05m |
| Altre spese | US$273.81m |
| Utili | US$6.24m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 0.043 |
| Margine lordo | 78.85% |
| Margine di profitto netto | 1.76% |
| Rapporto debito/patrimonio netto | 8.0% |
Come si è comportato MDXG nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/24 06:25 |
| Prezzo dell'azione a fine giornata | 2026/08/21 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
MiMedx Group, Inc. è coperta da 10 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| William Plovanic | Canaccord Genuity |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |